EMS in Viracept-Initial ('traditional') assessment of risk to patients based on linear dose response relations

Toxicology Letters

Volumn 190, Issue 3, 2009, Pages 266-270

  Gocke, Elmar ^a   Müller, Lutz ^a   Pfister, Thomas ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Alkylating agent; Birth defects; Cancer; Genotoxic impurity; In vivo genotoxicity; Risk assessment

Indexed keywords

ANTIRETROVIRUS AGENT; MESYLIC ACID ETHYL ESTER; MESYLIC ACID METHYL ESTER; NELFINAVIR; RAS PROTEIN;

ARTICLE; BIRTH DEFECT; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CARCINOGENICITY; CONCENTRATION (PARAMETERS); CYTOTOXICITY; DNA DAMAGE; DRUG CONTAMINATION; DRUG IMPURITY; DRUG QUALITY; DRUG SAFETY; GENE MUTATION; GENETIC DISORDER; GENETIC PREDISPOSITION; GENOTOXICITY; HEALTH HAZARD; HEMATOLOGIC MALIGNANCY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INHERITANCE; INTOXICATION; LETHAL DOSE; LINEAR SYSTEM; LUNG TUMOR; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; REFERENCE VALUE; REPRODUCTIVE TOXICITY; RISK ASSESSMENT; RISK FACTOR; SPERMATOGENESIS; TABLET FORMULATION; TERATOGENICITY; TOXICOKINETICS;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CARCINOGENICITY TESTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CONTAMINATION; ETHYL METHANESULFONATE; FEMALE; GENES, DOMINANT; GENES, LETHAL; GERM-LINE MUTATION; HIV PROTEASE INHIBITORS; HUMANS; LINEAR MODELS; MAMMARY NEOPLASMS, ANIMAL; METHYL METHANESULFONATE; MICE; MUTAGENICITY TESTS; NELFINAVIR; NO-OBSERVED-ADVERSE-EFFECT LEVEL; PREGNANCY; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RATS; RISK ASSESSMENT;

MUS; RATTUS; RODENTIA;

EID: 70350155150     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2009.04.030     Document Type: Article

References (26)

1. Adler I.D. Comparison of the duration of spermatogenesis between male rodents and humans. Mutat. Res. 352 (1996) 169-172
2. Baird P.A., Anderson T.W., Newcombe H.B., and Lowry R.B. Genetic disorders in children and young adults: a population study. Am. J. Hum. Genet. 42 5 (1988) 677-693
3. Barrington de Gonzales A., and Darby S. Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. Lancet 363 (2004) 345-351
4. Bartsch H., Terracini B., Malaveille C., Tomatis L., Wahrendorf J., Brun G., and Dodet B. Quantitative comparison of carcinogenicity, mutagenicity and electrophilicity of 10 direct-acting alkylating agents and of the initial O6:7-alkylguanine ratio in DNA with carcinogenic potency in rodents. Mutat. Res. 110 2 (1983) 181-219
5. Band P.R., Le N.D., Fang R., and Deschamps M. Carcinogenic and endocrine disrupting effects of cigarette smoke and risk of breast cancer. Lancet 360 (2002) 1044-1049
6. Bos P.M., Baars B.J., and van Raaij M.T. Risk assessment of peak exposure to genotoxic carcinogens: a pragmatic approach. Toxicol. Lett. 151 1 (2004) 43-50
7. Clapp N.K., Craig A.W., and Toya R.E. Oncogenicity by methyl methanesulfonate in mal RF mice. Science 161 (1968) 913-914
8. Doak S.H., Jenkins G.J., Johnson G.E., Quick E., Parry E.M., and Parry J.M. Mechanistic influences for mutation induction curves after exposure to DNA-reactive carcinogens. Cancer Res. 15 67 (2007) 3904-3911
9. Ehling U.H., and Neuhauser-Klaus A. Induction of specific-locus mutations in male mice by ethyl methanesulfonate (EMS). Mutat. Res. 227 October (2) (1989) 91-95
10. Engels E.A., Pfeiffer R.M., Goedert J.J., Virgo P., McNeel T.S., Scoppa S.M., and Biggar R.J. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 20 (2006) 1645-1654
11. Favor J., Sund M., Neuhauser-Klaus A., and Ehling U.H. A dose-response analysis of ethylnitrosourea-induced recessive specific-locus mutations in treated spermatogonia of the mouse. Mutat. Res. 231 1 (1990) 47-54
12. Frei J.V., Swenson D.H., Warren W., and Lawley D.W. Alkylation of deoxyribonucleic acid in vivo in various organs of C57BL mice by the carcinogens N-methyl-N-nitrosourea, N-ethyl-N-nitrosourea and ethyl methanesulphonate in relation to induction of thymic lymphoma. Biochem. J. 174 (1974) 1031-1044
13. Gerber C., and Toelle H.-G. What happened: the chemistry side of the incident with EMS contamination in Viracept tablets. Toxicol. Lett. 190 (2009) 248-253
14. Gocke E., Ballantyne M., Whitwell J., and Müller L. MNT and Muta™mouse studies to define the in vivo dose response relations of the genotoxicity of EMS and ENU Toxicol. Lett. 190 (2009) 286-297
15. Gold L.S., Slone T.H., Manley N.B., Garfinkel G.B., Hudes E.S., Rohrbach L., and Ames B.N. The carcinogenic potency database: analyses of 4000 chronic animal cancer experiments published in the general literature and by the U.S. National Cancer Institute/National Toxicology Program. Environ. Health Perspect. 96 December (1991) 11-15
16. Isaacs J.T. Genetic control of resistance to chemically induced mammary adenocarcinogenesis in the rat. Cancer Res. 46 8 (1986) 3958-3963
17. Huggins C., Grand L.C., and Brillantes F.P. Mammary cancer induced by a single feeding of polymucular hydrocarbons, and its suppression. Nature 189 (1961) 204-207
18. Lavé T., Paehler A., Grimm H.P., and Birnboeck H. In vivo and in vitro characterization of ethyl methanesulfonate pharmacokinetics in animal and man. Toxicol Lett. 190 (2009) 303-309
19. Müller L., Mauthe R.J., Riley C.M., Andino M.M., Antonis D.D., Beels C., DeGeorge J., De Knaep A.G., Ellison D., Fagerland J.A., Frank R., Fritschel B., Galloway S., Harpur E., Humfrey C.D., Jacks A.S., Jagota N., Mackinnon J., Mohan G., Ness D.K., O'Donovan M.R., Smith M.D., Vudathala G., and Yotti L. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. Regul. Toxicol. Pharmacol. 44 3 (2006) 198-211
20. Müller L., and Singer T. EMS in Viracept-a compilation of events in 2007 and 2008 from the preclinical point of view. Toxicol. Lett. 190 (2009) 243-247
21. Müller L., Gocke E., Lavé T., and Pfister T. Ethyl methanesulfonate toxicity in Viracept-a comprehensive human risk assessment based on threshold data for genotoxicity. Toxicol. Lett. 190 (2009) 317-329
22. Platzek T., Bochert G., and Meister R. Embryotoxicity induced by alkylating agents. 9. Low dose prenatal-toxic risk estimation of ethyl methanesulfonate based on no-observed-adverse-effect-level risk factor approach, dose-response relationships, and molecular dosimetry. Teratogen. Carcinogen. Mutagen. 15 2 (1995) 81-92
23. Sega G.A. A review of the genetic effects of ethyl methanesulfonate. Mutat. Res. 134 2-3 (1984) 113-142
24. Segal A., and Sellakumar A. Inducibility of thymic lymphomas in female Hsd: (ICR)BR mice following subcutaneous injection of ethyl- and isopropyl methanesulfonate. Cancer Lett. 44 (1989) 199-204
25. Ueo H., Takaki R., Yamagami H., and Sugimachi K. Mammary carcinoma induced by oral administration of ethyl methanesulphonate. Determination of some of the parameters affecting tumor induction. Carcinogenesis 2 12 (1981) 1223-1228
26. Yao R., Wang Y., Lu Y., Lemon W.J., End D.W., Grubbs C.J., Lubet R.A., and You M. Efficacy of the farnesyltransferase inhibitor R115777 in a rat mammary tumor model: role of Ha-ras mutations and use of microarray analysis in identifying potential targets. Carcinogenesis 27 (2006) 1420-1431